Latest Filings

Issuer Activity

Insider Overview :: Cardiome Pharma Corp. (T:COM) [?]
Business Focus: Biopharmaceuticals Share on StockTwits
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET July 29th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jun 30/14 Jun 27/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -2,000 $8.65
Jun 30/14 Jun 26/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,500 $8.65
Jun 27/14 Jun 25/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -2,000 $8.64
Jun 27/14 Jun 25/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -300 $8.63
Jun 27/14 Jun 24/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $8.77
Jun 27/14 Jun 23/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,100 $8.77
Jun 27/14 Jun 23/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -3,000 $8.60
Mar 13/14 Mar 11/14 Fortress Investment Group LLC Control or Direction Common Shares 15 - Disposition under a prospectus -1,500,000 $10.00
Jun 17/14 Apr 12/13 McMasters, David D. Direct Ownership Options 37 - Stock split or consolidation -48,000 $0.330
Jun 17/14 Apr 12/13 McMasters, David D. Direct Ownership Options 37 - Stock split or consolidation -140,000 $0.340
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET July 29th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jun 30/14 Jun 27/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -2,000 $8.65
Jun 30/14 Jun 26/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,500 $8.65
Jun 27/14 Jun 25/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -2,000 $8.64
Jun 27/14 Jun 25/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -300 $8.63
Jun 27/14 Jun 24/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $8.77
Jun 27/14 Jun 23/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,100 $8.77
Jun 27/14 Jun 23/14 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -3,000 $8.60
Jun 17/14 Apr 12/13 McMasters, David D. Direct Ownership Options 37 - Stock split or consolidation -48,000 $0.330
Jun 17/14 Apr 12/13 McMasters, David D. Direct Ownership Options 37 - Stock split or consolidation -140,000 $0.340
Mar 13/14 Mar 11/14 Fortress Investment Group LLC Control or Direction Common Shares 15 - Disposition under a prospectus -1,500,000 $10.00
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for COM on July 29, 2014 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Key People
Robert W. Rieder
Chairman of the Board
William L. Hunter
President, Chief Executive Officer, Director
Jennifer Archibald
Chief Financial Officer
Sheila M. Grant
Chief Operating Officer
Karim Lalji
Chief Commercial Officer
 
Company Contact
Address: 6TH FLOOR, 6190 AGRONOMY RD.
VANCOUVER BC V6T 1Z3
Tel: N/A
Website: www.cardiome.com
IR: www.cardiome.com/investors
Business Overview
Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company's clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.
Financial Overview
For the three months ended 31 March 2014, Cardiome Pharma Corp. revenues increased from $60K to $7.6M. Net loss totaled $3.1M vs. income of $18.4M. Revenues reflect Revenue: Licensing fees increase from $60K to $1M. Net loss reflects Selling, general and administration increase from $2.2M to $8M (expense), Interest expense (income) decrease from $16K (income) to $254K (expense), Foreign exchange loss increase from $28K to $181K (expense).
Employees: 75 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $109.47M as of Mar 31, 2014
Annual revenue (TTM): $13.07M as of Mar 31, 2014
EBITDA (TTM): -$14.05M as of Mar 31, 2014
Net annual income (TTM): -$18.18M as of Mar 31, 2014
Free cash flow (TTM): -$25.78M as of Mar 31, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 16,520,072 as of May 2, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
ProMetic Life Sciences (T:PLI)
 
Cardiome Pharma Corp. Insider Report Only $20.00